![]() Thus, a single dose of RhoGAM will suppress the immune response after exposure to < 15 mL of Rh-positive red blood cells. 3 In efficacy studies, RhoGAM was shown to suppress Rh immunization in all subjects when given at a dose of > 20 μg per mL of Rh-positive red blood cells. Patients known or suspected to be at increased risk of FMH should be tested for FMH by qualitative or quantitative methods. Multiple doses of RhoGAM are required if a FMH exceeds 15 mL, an event that is possible but unlikely prior to the third trimester of pregnancy and is most likely at delivery. If delivery of the baby does not occur 12 weeks after the administration of the standard antepartum dose (at 26 to 28 weeks), a second dose is recommended to maximize protection antepartum.If delivery occurs within three weeks after the last antepartum dose, the postpartum dose may be withheld, but a test for fetal-maternal hemorrhage should be performed to determine if exposure to > 15 mL of red blood cells has occurred.Administer RhoGAM every 12 weeks starting from first injection to maintain a level of passively acquired anti-D.RhoGAM may be administered if MICRhoGAM is not available. If RhoGAM is administered early in pregnancy (before 26 to 28 weeks), there is an obligation to maintain a level of passively acquired anti-D by administration of RhoGAM at 12-week intervals.Īctual or threatened termination of pregnancy (spontaneous or induced) up to and including 12 weeks gestation If antepartum prophylaxis is indicated, it is essential that the mother receive a postpartum dose if the infant is Rh-positive. Pregnancy termination (spontaneous or induced) beyond 12 weeks gestation.Threatened pregnancy loss after 12 weeks gestation with continuation of pregnancy.Abdominal trauma or obstetrical manipulation.Amniocentesis, chorionic villus sampling (CVS) and percutaneous umbilical blood sampling (PUBS).Prophylaxis at 26 to 28 weeks gestationĪdminister within 72 hours of suspected or proven exposure to Rh-positive red blood cells resulting from:.This may be determined by use of qualitative or quantitative tests for fetal-maternal hemorrhage. Postpartum (if the newborn is Rh-positive)Īdditional doses of RhoGAM are indicated when the patient has been exposed to > 15 mL of Rh-positive red blood cells. * : After delivery, obstetric complications, and/or invasive procedures, the volume of the fetal-maternal hemorrhage must be determined to calculate the exact dose of RhoGAM required. ![]() Pregnancy and other obstetrical conditions Dose
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |